Expertise in
49
conditions

Dr. Joseph J. Merchant

Hematology
Office
1018 Duff Ave, 
Ames, IA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
49
conditions
Office
1018 Duff Ave, 
Ames, IA 

Overview

Joseph Merchant is a Hematologist practicing medicine in Ames, Iowa.

Dr. Merchant is highly rated in 49 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, participating in 74 clinical trials. Dr. Merchant is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in IA

Hospital Affiliations

Greene County Medical Center
Dallas County Hospital
Mary Greeley Medical Center
Unitypoint Health - Marshalltown
Boone County Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Pekin Life
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 18 Less Insurance Carriers -

Locations

Office
1018 Duff Ave, Ames, IA 50010
Other Locations
Mary Greeley Medical Center
1111 Duff Ave, Ames, IA 50010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

74 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
53
conditions
Expertise in
53
conditions
Referral may be required

Hy-Vee Drugstore Clinic Pharmacy (7007)

1215 Duff Ave, 
Ames, IA 
 (0.2 miles away)
515-239-4432
Languages Spoken:
English, Hindi, Kanarese, Marathi
See accepted insurances
Accepting New Patients

Venkatesh Rudrapatna is a Hematologist practicing medicine in Ames, Iowa. Dr. Rudrapatna is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Anemia, Thrombocytopenia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Ureteroscopy. Dr. Rudrapatna is currently accepting new patients.

Expertise in
103
conditions
Dr. Tara Graff
Hematology | Oncology
Expertise in
103
conditions
Dr. Tara Graff
Hematology | Oncology
Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300, 
Des Moines, IA 
 (30.0 miles away)
515-247-3970
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Graff, DO, specializes in Hematology/Oncology at Mission Blood + Cancer in Des Moines, Iowa.Medical interests:Dr. Graff has led several clinical research projects and has published many original oncology and hematology articles.Certifications: Internal Medicine; Medical OncologyMedical School: Lake Erie College of Osteopathic Medicine, Bradenton, FL Residency:Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital Fellowship: Medical College of Wisconsin; Froedtert Memorial Lutheran Hospital. Dr. Graff is highly rated in 103 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Plasmacytoma, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Graff is currently accepting new patients.

Expertise in
105
conditions
Dr. Thomas Buroker
Hematology | Oncology
Expertise in
105
conditions
Dr. Thomas Buroker
Hematology | Oncology
Referral may be required

John Stoddard Cancer Center

1200 Pleasant St, 
Des Moines, IA 
 (30.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dr. Thomas Buroker completed his undergraduate work at The University of Iowa where he graduated in 1964. He went on to graduate from the College of Osteopathy Medical and Surgery (now the Des Moines University). Dr. Buroker completed a residency at the Grace Hospital in Detroit. He completed a fellowship in Medical Oncology at Wayne State University Medical School in Detroit. Dr. Buroker is highly rated in 105 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Lung Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Buroker is currently accepting new patients.

Frequently Asked Questions about Dr. Joseph J. Merchant

How do I make an appointment with Dr. Joseph J. Merchant?

You can book an appointment with Dr. Joseph J. Merchant by calling their office at 515-663-8621. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph J. Merchant a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph J. Merchant is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph J. Merchant specialize in?

While Dr. Joseph J. Merchant is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph J. Merchant accept my insurance?

Dr. Joseph J. Merchant accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 515-663-8621 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merchant's expertise for a condition
ConditionClose
    View All 45 Advanced Conditions
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile